Adaptimmune Therapeutics plc
Balance Sheet
| Line Item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $26.1M | $41.1M | $91.1M | $116.7M | $211.8M | $140.7M | $144.0M | $90.1M |
| Accounts Receivable | $9.3M | $4.4M | $1.5M | $12.5M | $2.3M | $8.4M | $821.0K | $789.0K |
| Inventory | $11.4M | $11.8M | $7.3M | $1.9M | — | — | — | — |
| Total Current Assets | $78.1M | $103.0M | $188.2M | $244.2M | $253.8M | $186.9M | $207.6M | $219.4M |
| Property, Plant & Equipment | $28.2M | $29.7M | $31.3M | $44.8M | $45.9M | $48.3M | $50.9M | $52.6M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $3.8M | $3.8M | $3.9M | $4.3M | $996.0K | $524.0K | $330.0K | $384.0K |
| Total Assets | $130.6M | $158.1M | $246.0M | $317.4M | $321.7M | $258.0M | $282.6M | $296.6M |
| Liabilities | ||||||||
| Accounts Payable | $9.4M | $5.7M | $8.7M | $9.1M | $7.5M | $6.6M | $8.1M | $13.9M |
| Total Current Liabilities | $51.5M | $51.1M | $64.5M | $63.5M | $82.1M | $66.4M | $72.8M | $75.1M |
| Long-Term Debt | $25.7M | $25.4M | $50.2M | $49.9M | $25.0M | — | — | — |
| Total Liabilities | $201.6M | $195.5M | $234.1M | $237.4M | $225.4M | $233.6M | $243.1M | $208.5M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.17B | $-1.14B | $-1.09B | $-1.02B | $-1.00B | $-1.07B | $-1.02B | $-975.3M |
| Total Stockholders' Equity | $-71.0M | $-37.4M | $11.8M | $80.0M | $96.3M | $24.4M | $39.5M | $88.1M |